Program Director will Sample Clauses

Program Director will. ▪ Be responsible for developing, implementing, and maintaining program operations in accordance with the requirements of this Agreement. ▪ Be responsible for ensuring compliance with all policies and guidelines, stay current with any changes and updates. ▪ Review cases in the ETO system for content on a quarterly basis. ▪ Ensure progress notes are accurate and timely. Be able to provide case notes when requested by the County. ▪ Prepare all required reports. ▪ Prepare, administer and monitor the program budget to ensure the accomplishment of program and service objectives within budget restrictions. ▪ Hire, train and supervise Program Managers who have clinical and community based experience, preferably with masters level education. ▪ Oversee the hiring, training and supervision of the Program Managers, Intake Worker and Case Managers. Staff must reflect the region’s demographic. Case Managers will be culturally and linguistically appropriate for the population to be served. ▪ Be responsible for the day-to-day management of the collaborative program. ▪ Hire, train, supervise and coordinate the Intake Worker and Case Managers. ▪ Be responsible for reviewing Path One and Path Two referrals and service plans. ▪ Coordinate and participate in the implementation of differential response, its goals, objectives, policies, and procedures. ▪ Ensure cases are up-to-date and case information is current to ensure validity and accuracy of reports. ▪ Read progress notes, review cases in the ETO system for content with staff ands ensure cases are up-to-date at least on a monthly basis. ▪ Ensure the quality and quantity of the home visits. This includes shadowing case managers on home visits once per quarter per worker. ▪ Provide individual and group supervision, including sign-off on closed client files, will be an additional quality control. ▪ Participate in the evaluation of the effectiveness of DR. ▪ Conduct regular meetings with DR staff to ensure all appropriate policies and guidelines are followed. ▪ Coordinate all community efforts around DR to ensure seamless process for families. ▪ Act as liaison and maintain an effective working relationship with Human Services Agency, FRCs, Core Service Agencies, community-based public and private organizations, and the community. ▪ Act as advocate and spokesperson in the community in support of DR programs and services.
View SourceView Similar (2)
Program Director will. Supervise the four (4) Case Managers and one (1) Mental Health Clinician and be responsible for reviewing Path One and Path Two referrals and service plans. - Assign referrals to Case Managers. - Coordinate and participate in the implementation of differential response, its goals, objectives, policies, and procedures. - Ensure cases are up-to-date and case information is current to ensure validity and accuracy of reports. - Participate in the evaluation of the effectiveness of DR. - Conduct regular meetings with DR staff to ensure all appropriate policies and guidelines are followed. - Coordinate all community efforts around DR to ensure seamless process for families. - Act as liaison and maintain an effective working relationship with HSA, FRCs, ▇▇▇▇▇▇▇ ▇▇▇▇ ▇▇▇▇, public and private organizations, and the community. - Act as advocate and spokesperson in the community in support of DR programs and services.
View SourceView Similar (2)
Program Director will. Be responsible for developing, implementing, and maintaining program operations at in accordance with the requirements of this Agreement.
View Source

Related to Program Director will

  • TRANSITION COMMITTEE A transition committee comprised of the employee representatives and the employer representatives, including the Crown, will be established by January 31, 2016 to address all matters that may arise in the creation of the Trust.

  • Selection Committee A. Each building site will appoint a selection committee for the TLS. The committee shall be comprised of equal numbers of teachers and administrators and at least one teacher will be appointed by the Des Moines Education Association. B. The committee will accept and review application for a TLS position and will make recommendations to the hiring administrator. In developing recommendations, the committee will utilize measures of teacher effectiveness and professional growth, consider the needs of the school district and review the performance and professional development of the applicants. Teachers who are selected must meet all of the qualification contained in the TLS grant and contained in the law.

  • Training Committee The parties to this Agreement may form a Training Committee. The Training Committee will be constituted by equal numbers of Employer nominees and ETU employee representatives and have a charter which clearly states its role and responsibilities. It shall monitor the clauses of this Agreement which relate to training and ensure all employees have equal access to training.

  • Calendar Committee A Calendar Committee shall be appointed by the Superintendent to make non-binding recommendations, no later than March of each calendar year, to the Board. The committee shall include the President of the Association, or a bargaining unit designee, and one (1) additional member of the Association. It is understood that said committee shall include appointees of the Superintendent and may also include bargaining unit members from each designated exclusive employee representative which negotiates with the Board in accordance with §§6-408 and/or 6-510 of the Education Article to the Annotated Code of Maryland.

  • Joint Steering Committee Promptly after the Effective Date, the Parties will form a Joint Steering Committee (the “JSC”) composed of an equal number of employees of each of Curis and Genentech, but in no event to exceed four (4) members from each Party. The JSC shall determine the specific goals for the Collaboration, shall manage the ongoing research conducted under the Collaboration in accordance with the Research Plan, shall monitor the progress and results of such work, and shall oversee and coordinate the development and commercialization of Compounds (other than Collaboration Products); provided, however, that the JSC shall not have decision-making authority with respect to the development and commercialization of Collaboration Products, which shall be governed by the CSC. The presence of at least one (1) representative of each Party shall constitute a quorum for the conduct of any JSC meeting. All decisions of the JSC shall require unanimous approval, with the representatives of each Party collectively having one (1) vote, provided in the event of a deadlock, the issue shall be referred to the Chief Executive Officer of Curis and the Senior Vice President of Research of Genentech, or their respective designees, who shall promptly meet and attempt in good faith to resolve such issue within thirty (30) days. If such executives cannot resolve such matter, then Genentech shall have final decision-making authority with regard to decisions regarding the Collaboration (including, without limitation, the JSC’s designation of a Compound as either a Lead Product or Excluded Product); provided, however, that in no event shall Genentech have the right or power to take any of the following actions without the approval of Curis’ representatives on the JSC: (a) approve the initial Research Plan (an outline of which has been agreed upon by the Parties as of the Effective Date); (b) amend or modify this Agreement or the Research Plan; (c) resolve any such matter in a manner that conflicts with the provisions of this Agreement (including, without limitation, the Research Plan); (d) make any decision with respect to the development or commercialization of Curis Products; or (e) make any decision with respect to the prosecution, maintenance, defense or enforcement of any Curis Patents. The JSC shall meet at such frequency as the JSC agrees, except that, until the filing of the first IND for a Lead Product utilizing Systemic Delivery in a Major Market, the JSC shall meet on at least a quarterly basis. Meetings of the JSC, and JSC dispute resolution meetings between Curis’ Chief Executive Officer and Genentech’s Senior Vice President of Research (or their designees), may be conducted by videoconference, teleconference or in person, as agreed by the Parties, and the Parties shall agree upon the time and place of meetings. A reasonable number of additional representatives of a Party may attend meetings of the JSC in a non-voting capacity. The JSC shall exist for so long as either any work is being conducted under the Research Plan or any Compound is being developed or commercialized by Genentech, Curis, or any of their respective Affiliate(s) or sublicensee(s) in any Major Market. The JSC shall also be responsible for designating one or more representatives of each Party with expertise in patent law (which individuals need not be members of the JSC) to oversee intellectual property matters relating to the Collaboration, subject to the provisions of Article 10, and such patent committee shall coordinate with and report to the JSC.